{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274183","form_type":"8-K","ticker":"KMTS","cik":"0001877184","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.946951+00:00","generated_at":"2026-05-16T22:39:10.227225+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kestra's ASSURE wearable defibrillator achieves 100% conversion in largest real-world study","bullets":["21,612-patient ACE-PAS trial met primary effectiveness endpoint: 100% successful conversion for VT/VF events.","Inappropriate-shock rate of 0.0065 per patient-month, below prespecified safety performance goal.","94% of patients experienced no false positive shock alarms; median wear time >23 hours per day.","2.6% of patients had at least one life-threatening VT/VF event, highlighting early risk.","Results presented as late-breaking science at AHA Scientific Sessions 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274183","json":"https://secwatch.observer/filing/0001193125-25-274183.json","markdown":"https://secwatch.observer/filing/0001193125-25-274183.md","text":"https://secwatch.observer/filing/0001193125-25-274183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525274183/0001193125-25-274183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525274183/ck0001877184-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:39:10.227225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}